The purpose of this guidance is to help sponsors in the development of anti-rabies virus monoclonal antibody (mAb) cocktails as an alternative to anti-rabies virus immunoglobulin (RIG) as the passive immunization component of post-exposure prophylaxis (PEP) for the prevention of rabies when given immediately after contact with a rabid or possibly rabid animal. This draft guidance is intended to serve as a focus for continued discussions among the Division of Antivirals, sponsors, the academic community, and the public. This guidance does not address the development of rabies vaccines, products to treat rabies, or mAbs for other indications. The recommendations in this guidance relate to studies to be submitted in support of a biologics license application (BLA) submission under section 351 of the Public Health Service Act (42 U.S.C. § 262) and implementing regulations at 21 CFR part 601.